4Fujimura T, Okuyama R, Ito Y, Aiba S. Profiles of Foxp3+ regu-latory T cells in eczematous dermatitis, psoriasis vulgaris andmycosis fungoides. Br J Dermatol, 2008, 158(6): 1256-1263.
5Baecher-Allan C, Wolf E, Hailer DA. MHC class II expressionidentifies functionally distinct human regulatory T cells J Immunol,2006, 176(8): 4622-4631.
4Bordere AC,Lambert J,van Geel N.Current and emerging therapy for the management of vitiligo [J].Clin Cosmet Investig Dermatol, 2009,2:15-25.
5Tu CX,Jin WW,Lin M,et al.Levels ofTGF-13 (0 in serum and culture supematants of CD4 (~)CD25 (~) T cells from patients with non-segmental vitiligo[J].Arch Dermatol Res,2011,303(9):685-689.
6Caproni M,Torchia D,Antiga E,et al. The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis [J].J Clin Immunol,2006,26(4):370-375.
7Berti S,Buggiani G,Lotti T.Use of tacrolimus ointment in vitiligo alone or in combination therapy [J]. Skin Therapy Lett,2009,14(4): 5-7.
8Lan CC,Chen GS,Chiou MH,et al.Fk506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes:possible mechanisms of how tacrolimus ointment induces repigrnentation in patients with vitiligo [J].Br J Dermatol,2005,153(3):498-505.
